Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer—study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II
Open Access
- 6 January 2021
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-11
Abstract
Background: Diabetes and its sequelae such as diabetic foot ulcer are rising health hazards not only in western countries but all over the world. Effective, yet safe treatments are desperately sought for by physicians, healthcare providers, and of course patients. Methods/design: APOSEC, a novel, innovative drug, is tested in the phase I/II study MARSYAS II, where its efficacy to promote healing of diabetic foot ulcers will be determined. To this end, the cell-free secretome of peripheral blood mononuclear cells (APOSEC) blended with a hydrogel will be applied topically three times weekly for 4 weeks. APOSEC is predominantly effective in hypoxia-induced tissue damages by modulating the immune system and enhancing angiogenesis, whereby its anti-microbial ability and neuro-regenerative capacity will exert further positive effects. In total, 132 patients will be enrolled in the multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging phase I/II study and treated with APOSEC at three dose levels or placebo for 4 weeks, followed by an 8-week follow-up period to evaluate safety and efficacy of the drug. Wound area reduction after 4 weeks of treatment will serve as the primary endpoint. Conclusion: We consider our study protocol to be suitable to test topically administered APOSEC in patients suffering from diabetic foot ulcers in a clinical phase I/II trial. Trial registration: EudraCT 2018-001653-27. Registered on 30 July 2019. ClinicalTrials.gov NCT04277598. Registered on 20 February 2020. Title: “A randomized, placebo-controlled, double-blind study to evaluate safety and dose-dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer (MARSYAS II)”Keywords
Funding Information
- Aposcience AG
This publication has 35 references indexed in Scilit:
- Stem cells conditioned medium: a new approach to skin wound healing managementCell Biology International, 2013
- Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilationBasic Research in Cardiology, 2012
- Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical studyBasic Research in Cardiology, 2011
- Intravenous and intramyocardial injection of apoptotic white blood cell suspensions prevents ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarctionBasic Research in Cardiology, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardiumEuropean Journal of Clinical Investigation, 2009
- Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarctionEuropean Heart Journal, 2008
- Long-Term Outcome and Disability of Diabetic Patients Hospitalized for Diabetic Foot UlcersDiabetes Care, 2008
- Early healing rates and wound area measurements are reliable predictors of later complete wound closureWound Repair and Regeneration, 2008
- The Independent Contributions of Diabetic Neuropathy and Yasculopatny in Foot Ulceration: How great are the risks?Diabetes Care, 1995